Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
US-2024158357-A1 · May 16, 2024 · US
Dual small molecule inhibitors of cancer and angiogenesis
US9133136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9133136-B2 |
| Application number | US-201414166200-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 28, 2014 |
| Priority date | Jun 1, 2004 |
| Publication date | Sep 15, 2015 |
| Grant date | Sep 15, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.
First claim
Opening claim text (preview).
What is claimed is: 1. A method to treat retinal or choroidal neovascularization or a disease associated therewith in a subject in need thereof comprising administering to said subject an effective amount of at least one compound having the general structure of formula I: wherein R 1 , R 3 , and R 4 are independently selected from the group consisting of NO 2 , H, halo, C 1 -C…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9133136B2 cover?
- The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.
- Who is the assignee on this patent?
- Univ Virginia Patent Found
- What technology area does this patent fall under?
- Primary CPC classification C07D239/91. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).